This multi-national study, enrolled 206 men, was randomized 2:1 to the UroLift System versus palcebo control.
The UroLift System is being investigated as a minimally invasive device designed to increase the opening of the urethra without removing prostate tissue.
Small UroLift Implants are permanently placed in the urethra through the UroLift delivery device, so as to obstruct prostate tissue not to go out of the way.
University of Texas Southwestern Urology professor and chairman and study co-principal investigator Claus Roehrborn said the LIFT Study is designed to provide comprehensive information for FDA evaluation.
"If the UroLift technology keeps performing as it has in previous, single-arm studies, we look forward to offer this new product to US patients," Roehrborn said.
